CP
FENC icon

Clayton Partners’s Fennec Pharmaceuticals FENC Stock Holding History

Clayton Partners’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40,540
Closed -$256K – 36
2024
Q4 		$256K Buy
+40,540
New +$208K 0.18% 38

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clayton Partners's FENC Position: Q1 2025 in Review

Clayton Partners sold out of Fennec Pharmaceuticals (FENC) in Q1 2025, closing a stake of 40,540 shares — an estimated $256K sold.

Clayton Partners first reported a position in FENC in Q4 2024 and held it in 1 quarter. The position peaked at $256K in Q4 2024. 68 funds tracked by Wall St. Rank hold FENC as of Q1 2025.

  • Clayton Partners reported no remaining Fennec Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Clayton Partners sold 40,540 Fennec Pharmaceuticals shares in Q1 2025, an estimated $256K.
  • Clayton Partners first reported a position in Fennec Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Clayton Partners's Fennec Pharmaceuticals position peaked at $256K in Q4 2024.
  • 68 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2025.

Based on Clayton Partners's 13F filing for Q1 2025, filed 15 May 2025.